Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24962026
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the
AMPA-selective glutamate receptor-4
#MMPMID24962026
von Roemeling CA
; Radisky DC
; Marlow LA
; Cooper SJ
; Grebe SK
; Anastasiadis PZ
; Tun HW
; Copland JA
Cancer Res
2014[Sep]; 74
(17
): 4796-810
PMID24962026
show ga
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney
cancer and has the highest propensity to manifest as metastatic disease. Recent
characterizations of the genetic signature of ccRCC have revealed several factors
correlated with tumor cell migration and invasion; however, the specific events
driving malignancy are not well defined. Furthermore, there remains a lack of
targeted therapies that result in long-term, sustainable response in patients
with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is
overexpressed specifically in ccRCC primary tumors and metastases, and that it
contributes to tumor cell viability and promotes cell migration through its
interaction with the ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy
for patients with ccRCC diagnosed with or at risk of developing metastatic
disease.
free
free
free
